Why Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up

Simply Wall St.01-10

Sichuan Kelun-Biotech Biopharmaceutical recently reported that its TROP2-directed ADC sacituzumab tirumotecan, combined with pembrolizumab, received Breakthrough Therapy Designation in China for first...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602300920?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-10 01:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602300920","market":"sg","top_or_hot":-1,"title":"Why Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up","media":"Simply Wall St.","content":"<div>\n<p>Sichuan Kelun-Biotech Biopharmaceutical recently reported that its TROP2-directed ADC sacituzumab tirumotecan, combined with pembrolizumab, received Breakthrough Therapy Designation in China for first...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/why-sichuan-kelun-biotech-biopharmaceutical-sehk6990-is-up-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Up 18.9% After Breakthrough ADC Milestones And Global Tie-Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-10 01:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/why-sichuan-kelun-biotech-biopharmaceutical-sehk6990-is-up-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sichuan Kelun-Biotech Biopharmaceutical recently reported that its TROP2-directed ADC sacituzumab tirumotecan, combined with pembrolizumab, received Breakthrough Therapy Designation in China for first...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/why-sichuan-kelun-biotech-biopharmaceutical-sehk6990-is-up-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物-B","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/why-sichuan-kelun-biotech-biopharmaceutical-sehk6990-is-up-1","article_id":"2602300920","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/why-sichuan-kelun-biotech-biopharmaceutical-sehk6990-is-up-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602300920","pubTimestamp":1767979187,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sichuan Kelun-Biotech Biopharmaceutical recently reported that its TROP2-directed ADC sacituzumab tirumotecan, combined with pembrolizumab, received Breakthrough Therapy Designation in China for first-line PD-L1-positive NSCLC, while its ITGB6-targeted ADC SKB105 secured IND approval for advanced solid tumors and a new global collaboration with Crescent Biopharma was announced.\nThese developments, alongside multiple ongoing registrational and Phase 3 trials and structured distribution and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物-B","BK4231":"零售房地产信托","ADC":"艾格里房产","BK4080":"零售业房地产投资信托","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK1161":"生物科技"},"translate_title":"为什么四川科伦生物制药（SEHK：6990）在突破ADC里程碑和全球合作后上涨18.9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1.5,"06990":0.9},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical recently reported that its TROP2-directed ADC sacituzumab tirumotecan, combined with pembrolizumab, received Breakthrough Therapy Designation in China for first-line PD-L1-positive NSCLC, while its ITGB6-targeted ADC SKB105 secured IND approval for advanced solid tumors and a new global collaboration with Crescent Biopharma was announced. These developments, alongside multiple ongoing registrational and Phase 3 trials and structured distribution and reimbursement arrangements in China, underline how Kelun-Biotech is building an oncology franchise that reaches both domestic and international markets. We’ll now examine how Breakthrough Therapy Designation for sacituzumab tirumotecan reshapes Sichuan Kelun-Biotech’s investment narrative and pipeline positioning. Trump has pledged to \"unleash\" American oil and gas and these 22 US stocks have developments that are poised to benefit.AdvertisementWhat Is Sichuan Kelun-Biotech Biopharmaceutical's Investment Narrative?To own Sichuan Kelun-Biotech, you need to believe its transition from a single-asset story into a diversified oncology platform can justify a rich valuation despite ongoing losses and a fast-rising share price. The new Breakthrough Therapy Designation for sacituzumab tirumotecan in first-line PD-L1-positive NSCLC sharpens the near-term catalyst map: regulatory decisions in China on multiple sac-TMT indications now sit at the center of the equity story, while the OptiTROP-Lung05 data give that narrative more clinical backing. At the same time, the IND green light for SKB105 and the Crescent Biopharma tie-up expand the medium-term pipeline and ex-China optionality rather than changing the next 12 months, where sac-TMT approvals, NRDL access and execution of the China Resources Kelun distribution framework remain the key swing factors. The biggest risk is that the current premium pricing already reflects a lot of this optimism. However, one important concentration risk in the oncology portfolio is easy to underestimate.\n\nSichuan Kelun-Biotech Biopharmaceutical's shares have been on the rise but are still potentially undervalued by 44%. Find out what it's worth.Exploring Other PerspectivesSEHK:6990 1-Year Stock Price Chart Two Simply Wall St Community fair value views span about HK$532.76 to HK$847.77, underscoring how differently retail investors frame Kelun-Biotech’s upside. Set that against the recent Breakthrough Therapy news, which pulls regulatory timing and execution risk into much sharper focus for the next leg of performance.Explore 2 other fair value estimates on Sichuan Kelun-Biotech Biopharmaceutical - why the stock might be worth as much as 78% more than the current price!Build Your Own Sichuan Kelun-Biotech Biopharmaceutical NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Sichuan Kelun-Biotech Biopharmaceutical research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Sichuan Kelun-Biotech Biopharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sichuan Kelun-Biotech Biopharmaceutical's overall financial health at a glance.Want Some Alternatives?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Uncover the next big thing with financially sound penny stocks that balance risk and reward.These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.We've found 11 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602300920","isCrawlerRequest":true}